GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » E10

Oncotelic Therapeutics (Oncotelic Therapeutics) E10 : $0.00 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncotelic Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Oncotelic Therapeutics was 61.60% per year. The lowest was -3.50% per year. And the median was 10.10% per year.

As of today (2024-05-14), Oncotelic Therapeutics's current stock price is $0.0369. Oncotelic Therapeutics's E10 for the quarter that ended in Dec. 2023 was $0.00. Oncotelic Therapeutics's Shiller PE Ratio of today is .


Oncotelic Therapeutics E10 Historical Data

The historical data trend for Oncotelic Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncotelic Therapeutics E10 Chart

Oncotelic Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.93 -2.65 - -1.03 -

Oncotelic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -0.91 -0.68 - -

Competitive Comparison of Oncotelic Therapeutics's E10

For the Biotechnology subindustry, Oncotelic Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncotelic Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncotelic Therapeutics's Shiller PE Ratio falls into.



Oncotelic Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncotelic Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Oncotelic Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -0.290 99.695 -0.376
201406 -0.230 100.560 -0.296
201409 -0.170 100.428 -0.219
201412 -0.110 99.070 -0.144
201503 -0.130 99.621 -0.169
201506 -0.130 100.684 -0.167
201509 -0.140 100.392 -0.180
201512 -0.150 99.792 -0.195
201603 -0.130 100.470 -0.167
201606 -0.140 101.688 -0.178
201609 -0.120 101.861 -0.152
201612 -0.130 101.863 -0.165
201703 -0.150 102.862 -0.189
201706 -0.150 103.349 -0.188
201709 -0.130 104.136 -0.162
201712 -0.090 104.011 -0.112
201803 -0.030 105.290 -0.037
201806 -0.020 106.317 -0.024
201809 -0.040 106.507 -0.049
201812 -0.053 105.998 -0.065
201903 -0.140 107.251 -0.169
201906 -0.020 108.070 -0.024
201909 -0.010 108.329 -0.012
201912 -0.050 108.420 -0.060
202003 -0.050 108.902 -0.059
202006 0.010 108.767 0.012
202009 -0.020 109.815 -0.024
202012 -0.040 109.897 -0.047
202103 -0.030 111.754 -0.035
202106 -0.010 114.631 -0.011
202109 -0.004 115.734 -0.004
202112 0.000 117.630 0.000
202203 -0.010 121.301 -0.011
202206 0.040 125.017 0.041
202209 -0.002 125.227 -0.002
202212 -0.020 125.222 -0.021
202303 -0.001 127.348 -0.001
202306 -0.020 128.729 -0.020
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Oncotelic Therapeutics  (OTCPK:OTLC) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncotelic Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Executives
Vuong Trieu officer: CHIEF EXECUTIVE OFFICER 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund officer: CHIEF BUSINESS OFFICER C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah officer: CHIEF FINANCIAL OFFICER 10 AGUILA, ALISO VIEJO CA 92656
Chulho Park officer: CHIEF TECHNOLOGY OFFICER 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King director
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun 10 percent owner, officer: Chief Medical Officer 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao 10 percent owner 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang 10 percent owner C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds director C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd director C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar officer: Chief Financial Officer 505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha officer: Controller 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080

Oncotelic Therapeutics (Oncotelic Therapeutics) Headlines